Responses
Regular and young investigator award abstracts
Clinical trials in progress
342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
Compose a Response to This Article
Other responses
No responses have been published for this article.
